Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab treat-and-extend versus PRN for diabetic macular edema
NL-OMON36659Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of ranibizumab in diabetic macular edema (DME) (3 arms), sponsored by Novartis. Primary endpoint: Primary efficacy endpoint. Started Sep 2010; status: active, not recruiting.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NL-OMON36659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36659.